As part of our ongoing aim to bring you reports of new developments, we have added a review which summarises a post hoc analysis of the long-term impact of anifrolumab versus placebo, in addition to standard therapy on lupus low disease activity state and definition of remission in systemic lupus erythematous attainment throughout four years of the TULIP trials.
Independent commentary for the review has been provided by Professor Paul Bird, a rheumatologist in private practice and conjoint Professor at UNSW.
Please login below to download this issue (PDF)